Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility
about
Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early diseaseEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateA commentary on TREAT: the trial of early aggressive drug therapy in juvenile idiopathic arthritis.Use of risk stratification to target therapies in patients with recent onset arthritis; design of a prospective randomized multicenter controlled trialDisease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world.Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints.Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study.Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatmentDevelopment of a multi-biomarker disease activity test for rheumatoid arthritisPerformance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria.Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis.Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large U.S. cohort.Determining the Lowest Optimally Effective Methotrexate Dose for Individual RA Patients Using Their Dose Response Relation in a Tight Control Treatment Approach.Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.Patient-initiated appointments compared with standard outpatient care for rheumatoid arthritis: a randomised controlled trialRheumatoid arthritis patients and rheumatologists approach the decision to escalate care differently: results of a maximum difference scaling experiment.Comparison of the systemic lupus erythematosus activity questionnaire and the systemic lupus erythematosus disease activity index in a black barbadian population.Evidence for treating rheumatoid arthritis to target: results of a systematic literature search.Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future.Rheumatoid arthritis disease measurement: a new old idea.Dose optimization of infliximab in patients with rheumatoid arthritis.S100A8/A9 as a biomarker for synovial inflammation and joint damage in patients with rheumatoid arthritis.Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task forceDrug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry.Does disease activity add to functional disability in estimation of utility for rheumatoid arthritis patients on biologic treatment?Optimal use of methotrexate: the advantages of tight control.Is there a place for nonbiological drugs in the treatment of rheumatoid arthritis?Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study.Computerised versus conventional methodology of radiographic joint destruction assessment in early rheumatoid arthritis.Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction.Sustained macrophage infiltration upon multiple intra-articular injections: an improved rat model of rheumatoid arthritis for PET guided therapy evaluation.Methotrexate compliance among patients with rheumatoid arthritis: the influence of disease activity, disease duration, and co-morbidity in a 10-year longitudinal study.Tight control of rheumatoid arthritis in a resource-constrained setting: a randomized controlled study comparing the clinical disease activity index and simplified disease activity index.Severe low back pain in patients with rheumatoid arthritis is associated with Disease Activity Score but not with radiological findings on plain X-rays.Repeat etanercept administration restores clinical response of patients with rheumatoid arthritis.Imaging and Methotrexate Response Monitoring of Systemic Inflammation in Arthritic Rats Employing the Macrophage PET Tracer [18F]Fluoro-PEG-Folate.Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype–positive rheumatoid arthritis patients
P2860
Q26753120-2B507A6D-3F8E-41F0-AE0F-0DEDEDCD729AQ26859134-6DC683F6-B2E9-4D25-88FE-3EFEEF841ED7Q31064321-5DC88587-288B-4326-A23B-D8EB7DBD95BCQ33470696-AB07A14E-BF46-4093-A5B0-7FDCAC05123FQ33747197-96BFE8C6-4E53-4D29-BB8D-1960E15622C0Q34033218-04DDBA59-7664-4CF0-A7C5-990128B2A91AQ34420269-A747D3FF-171A-4108-AD5A-CEDCC5D34DDDQ34563216-17A9C637-A9AC-4A23-B08C-C557197AA8D5Q34667793-AA99739A-66DB-4308-91E3-4ED676C03589Q35249630-2E47107A-6A07-4204-81BE-51EB395DFA79Q35569500-8AC00566-4092-4660-B13D-60789839B688Q35583230-36BC3753-C9DB-43F8-B89C-1FF604C0470AQ35961312-FAD7F67D-3538-4477-B081-356867CBCA37Q36677277-4DF5B223-B5C7-4D70-8843-5EFD16436E80Q36709339-61D146F7-31D2-4A26-B0F5-25494C583EB4Q36973563-48D52DE1-DDA2-4905-887A-0CBF1A7B157DQ37299358-3FF8A3E8-8E67-4E85-B715-C3C99718846FQ37710906-425EA832-2F7B-446E-BAF3-001B84B01F9AQ37882064-8C66EE9C-B0A9-4256-A2FB-EDD29A3DB547Q38065766-F2D839FB-6E68-4E3B-93F4-7D5307B2AD48Q38182728-F211A8C9-891A-4EC8-A229-463E258E817BQ38191587-34E21E26-031C-444D-A454-218A8E7A8F4EQ38476881-388CB15F-8943-41FA-AFA0-EEFCEECBA5BBQ38664981-18B9AC20-9220-4F70-8E80-F883105ED4B6Q40597614-57C6D205-65CD-48C7-9B2A-3D1A7F89FCF6Q41348602-B7B7BC6F-B5D3-4354-8CBB-A62807ACDA22Q41948703-6CBCB9E9-D400-4404-878F-A7F4C0BDC6BBQ42010067-001124AF-986E-479C-9F03-0724C647FB70Q42279180-6868A6A1-667C-4938-9440-7D3664DB2945Q42540679-1460AB26-E6EB-4937-A13B-CA0326697307Q43143053-8E394810-E518-4B10-9E2D-EE99B1D9B2A2Q43810717-FDCCBEFC-80D0-471C-A7EE-7610DA0CD7A6Q46988765-E30067A0-96A6-4D4F-BDB6-AB80D954FA3BQ51133170-CEF9B6C3-5118-4B36-8647-9B9AAE3214EDQ51417238-B25AF1CB-BA54-4B07-BB9F-657E8C25D344Q55263900-CEDE5944-DB0A-43D6-AF8B-EBC9A0A69556Q57221897-8B107603-2230-4E4A-B129-FF576DFDEA4A
P2860
Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility
@en
type
label
Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility
@en
prefLabel
Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility
@en
P2093
P2860
P356
P1476
Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility
@en
P2093
J W G Jacobs
J W J Bijlsma
M F Bakker
P2860
P304
P356
10.1136/ARD.2007.078360
P407
P478
66 Suppl 3
P577
2007-11-01T00:00:00Z